We hypothesized that the BET inhibitor JQ1 would promote a DNA repair-deficient phenotype, sensitizing NB cells to PARP inhibition by Olaparib, and sought to determine how MYCN amplification status may affect the efficacy of this combination therapy. The gene discussed is DNER; the disease is neuroblastoma.